Search Page

1

Cite

Share

Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.

Börgeson E, Godson C. Börgeson E, et al. Front Immunol. 2012 Oct 18;3:318. doi: 10.3389/fimmu.2012.00318. eCollection 2012. Front Immunol. 2012. PMID: 23087692 Free PMC article.

Cite

Share

2

Cite

Share

Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.

Brennan EP, Nolan KA, Börgeson E, Gough OS, McEvoy CM, Docherty NG, Higgins DF, Murphy M, Sadlier DM, Ali-Shah ST, Guiry PJ, Savage DA, Maxwell AP, Martin F, Godson C; GENIE Consortium. Brennan EP, et al. Among authors: borgeson e. J Am Soc Nephrol. 2013 Mar;24(4):627-37. doi: 10.1681/ASN.2012060550. Epub 2013 Mar 21. J Am Soc Nephrol. 2013. PMID: 23520204 Free PMC article.

Cite

Share

3

Cite

Share

Lipoxin A4 attenuates adipose inflammation.

Börgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C. Börgeson E, et al. FASEB J. 2012 Oct;26(10):4287-94. doi: 10.1096/fj.12-208249. Epub 2012 Jun 14. FASEB J. 2012. PMID: 22700871

Cite

Share

4

Cite

Share

Molecular circuits of resolution in renal disease.

Börgeson E, Godson C. Börgeson E, et al. ScientificWorldJournal. 2010 Jul 7;10:1370-85. doi: 10.1100/tsw.2010.120. ScientificWorldJournal. 2010. PMID: 20623097 Free PMC article. Review.

Cite

Share

5

Cite

Share

Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal fibrosis.

Börgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O'Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C. Börgeson E, et al. FASEB J. 2011 Sep;25(9):2967-79. doi: 10.1096/fj.11-185017. Epub 2011 May 31. FASEB J. 2011. PMID: 21628447

Cite

Share

6

Cite

Share

Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease.

Börgeson E, Johnson AM, Lee YS, Till A, Syed GH, Ali-Shah ST, Guiry PJ, Dalli J, Colas RA, Serhan CN, Sharma K, Godson C. Börgeson E, et al. Cell Metab. 2015 Jul 7;22(1):125-37. doi: 10.1016/j.cmet.2015.05.003. Epub 2015 Jun 4. Cell Metab. 2015. PMID: 26052006 Free PMC article.

Cite

Share

7

Cite

Share

AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin.

Börgeson E, Wallenius V, Syed GH, Darshi M, Lantero Rodriguez J, Biörserud C, Ragnmark Ek M, Björklund P, Quiding-Järbrink M, Fändriks L, Godson C, Sharma K. Börgeson E, et al. Diabetologia. 2017 Apr;60(4):729-739. doi: 10.1007/s00125-017-4211-9. Epub 2017 Feb 10. Diabetologia. 2017. PMID: 28188334 Free PMC article.

Cite

Share

8

Cite

Share

Obesity-induced changes in lipid mediators persist after weight loss.

Hernandez-Carretero A, Weber N, La Frano MR, Ying W, Lantero Rodriguez J, Sears DD, Wallenius V, Börgeson E, Newman JW, Osborn O. Hernandez-Carretero A, et al. Among authors: borgeson e. Int J Obes (Lond). 2018 Apr;42(4):728-736. doi: 10.1038/ijo.2017.266. Epub 2017 Nov 1. Int J Obes (Lond). 2018. PMID: 29089614 Free PMC article.

Cite

Share

9

Cite

Share

The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice.

Zhong L, Ding Y, Bandyopadhyay G, Waaler J, Börgeson E, Smith S, Zhang M, Phillips SA, Mahooti S, Mahata SK, Shao J, Krauss S, Chi NW. Zhong L, et al. Among authors: borgeson e. Diabetologia. 2016 Mar;59(3):582-91. doi: 10.1007/s00125-015-3815-1. Epub 2015 Dec 2. Diabetologia. 2016. PMID: 26631215

Cite

Share

10

Cite

Share

Obesity, immunomodulation and chronic kidney disease.

Börgeson E, Sharma K. Börgeson E, et al. Curr Opin Pharmacol. 2013 Aug;13(4):618-24. doi: 10.1016/j.coph.2013.05.011. Epub 2013 Jun 7. Curr Opin Pharmacol. 2013. PMID: 23751262 Free PMC article. Review.

Cite

Share